Singapore markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0900-0.0100 (-0.91%)
At close: 04:00PM EST
1.0800 -0.01 (-0.92%)
After hours: 07:52PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 140.89M
Enterprise value 183.26M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)1.09
Price/book (mrq)63.84
Enterprise value/revenue 1.44
Enterprise value/EBITDA -1.48

Trading information

Stock price history

Beta (5Y monthly) 2.49
52-week change 3-83.23%
S&P500 52-week change 315.38%
52-week high 36.8700
52-week low 30.9100
50-day moving average 31.3739
200-day moving average 33.9328

Share statistics

Avg vol (3-month) 33.54M
Avg vol (10-day) 32.27M
Shares outstanding 5129.26M
Implied shares outstanding 6129.26M
Float 897.49M
% held by insiders 16.68%
% held by institutions 181.36%
Shares short (14 Nov 2023) 423.37M
Short ratio (14 Nov 2023) 44.79
Short % of float (14 Nov 2023) 434.00%
Short % of shares outstanding (14 Nov 2023) 418.08%
Shares short (prior month 12 Oct 2023) 422.85M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin -111.03%
Operating margin (ttm)-15,294.52%

Management effectiveness

Return on assets (ttm)-25.16%
Return on equity (ttm)-538.57%

Income statement

Revenue (ttm)127.24M
Revenue per share (ttm)1.00
Quarterly revenue growth (yoy)-91.00%
Gross profit (ttm)-165.79M
EBITDA -130.53M
Net income avi to common (ttm)-141.27M
Diluted EPS (ttm)-1.1100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)169.91M
Total cash per share (mrq)1.32
Total debt (mrq)212.28M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.71
Book value per share (mrq)-0.12

Cash flow statement

Operating cash flow (ttm)-122.75M
Levered free cash flow (ttm)-91.02M